Loading Events

« All Events

  • This event has passed.

Webinar: Developing a Panel of Human Pluripotent Stem Cell-Derived Microglia to Model Neurodegenerative Diseases

July 21 | 10:00 am CDT - 11:00 am CDT

Event Navigation

View the webinar to learn about:

  • New human iPSC-derived microglia with diseased backgrounds for accurately modelling
    neurodegenerative diseases.
  • Analysis of disease specific anti-inflammatory and inflammatory responses to specific stimuli.
  • Microglia panel uses for a variety of in vitro applications, including investigation of the role of gene variants, co-culture models, among others.

Please complete this form to access the webinar video:


Presenters: Beatriz Freitas, PhD (Product Manager, FUJIFILM Cellular Dynamics, Inc.)
Simon Hilcove, PhD (Assoc. Director, Product Development, FUJIFILM Cellular
Dynamics, Inc.)

Abstract: Microglia, the resident immune cells of the brain, are key players in neuroinflammation and manifestation of neurodegenerative diseases. Recent studies have identified genes that are highly
expressed in microglia associated with an increased risk of developing Alzheimer’s disease (AD),
Parkinson’s disease (PD), Frontotemporal Dementia (FTD), or Amyotrophic Lateral Sclerosis (ALS), thus
propelling microglia to the forefront of neurodegenerative disease progression and emphasizing the
critical need of model systems to study microglia. Since primary human microglia from living donors are
not accessible for research, human induced pluripotent stem cell (iPSC)-derived microglia emerge as an
authentic human preclinical tool to mimic neurodegeneration and enable drug screening applications in
vitro, as well as co-culture with other neural cell types for drug candidate validation. Recent GWAS
studies have shown that genetically inherited variants apolipoprotein E4 (APOE4), presenilin 1 (PSEN1),
presenilin 2 (PSEN2), or amyloid precursor protein (APP), and the presence of specific Single Nucleotide
Polymorphisms (SNPs) within triggering receptor expressed on myeloid cells 2 (TREM2), CD33 or Siglec
3, ATP-binding cassette transporter A7 (ABCA7), have a strong association with increased disease risk of
AD. A panel of 12 human iPSCs from apparently healthy and diseased donors harboring many inherited
mutations were selected and successfully differentiated into cryopreserved hematopoietic progenitor
cells and microglia. In addition, microglia were also derived from engineered and non-engineered iPSCs
to create isogenic pairs with mutations in TREM2, A53T and MeCP2. End stage microglia retained the
presence of cell surface (CD45, CD11b and CD33) and intracellular (P2RY12, TREM-2, CX3CR1, IBA)
microglia-specific antigens, gene expression patterns and exhibited phagocytic function. In addition,
cryopreserved microglia retained the ability to be polarized towards an inflammatory or anti-
inflammatory subtype by specific stimuli. Thus, this panel of both normal and disease associated
microglia can be used to investigate the role of gene variants in human microglia, develop co-culture
applications with other neural cell types to create predictive in vitro models for neurodegenerative




July 21
10:00 am CDT - 11:00 am CDT


Fujifilm Cellular Dynamics, Inc.